Owing to possible incomplete assessment of the phenotypic features of affected individuals or late disease onset, the control databases may conceivably include patients with rare diseases such as (familial) MTC and MEN2 syndrome who carry pathogenic RET variants. This evidence concerns the gene RET and medullary thyroid gland carcinoma.